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microRNAs (miRNAs) are unique class of global gene regulators identified both in plants and animals. 
They can reduce protein levels of their target genes with a minor impact on the target genes mRNA. 
Levels of some miRNAs are found altered in cancers, so we might expect these regulatory molecules to 
be involved in the development of different carcinomas. The differential expression of certain miRNAs 
in various tumors might become a powerful tool to aid in the diagnosis and treatment of cancers. The 
precise biological roles of most miRNAs are still poorly understood and therefore, this review is an 
attempt to highlight the role and connections of human miRNA with different aspects of cancers.  
 





Several hundred genes in human genome encodes small 
actively functional RNA molecules (Meng et al., 2007) 
ranging in length from 21 to 23 nucleotides known as 
microRNAs (miRNAs) (Dong et al., 2010). These miRNAs 
hybridize to the 3’ untranslated region of target mRNAs 
causing repression at post-transcriptional level. Genes 
encoding these small molecules are found either inserted 
in introns as polycistronic clusters or in isolated regions of 
the genome (Jerome et al., 2007). They are conserved 
and important class of regulators functioning in diverse 
physiological and pathological phenomenon (Bagga and 
Pasquinelli, 2006) including apoptosis, proliferation, 
migration (Meng et al., 2007), hematopoietic cell differen-
tiation (Chen et al., 2004) and brain development. They 
remain stable in tissues, serum, plasma and other body 
fluids protected from the action of endogenous RNase 
(Lodes et al., 2009). More than 500 miRNAs have been 
identified in human genome regulating up to 30% of the 
protein coding genes (Rajewsky, 2006). 
Cancer is a complex and dynamic disease which 
involves a number of genetic alterations both in structure 
and function of genes. Traditional studies were focused 
on protein-coding genes and were considering them as 
the main players regulating cancers (Stahlhut and Slack, 
2006). Role of miRNAs as regulators of cancer related 
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few years (Jackson and Standart, 2007) and are con-
sidered one among the most important post-
transcriptional gene regulators in both plants and animals 
(Pillai et al., 2007). Factors activating or deactivating 
miRNAs in tumorigenesis were considered to cooperate 
with abnormalities of protein coding genes (Calin and 
Croce, 2006). Depending upon the target mRNA, they 
can function either as oncogenes or tumor suppressors 
(Wiseman et al., 2005). Molecular characterization of 
13q14 deletion in human chronic lymphocytic leukemia 
(CLL) suggested the involvement of miRNAs (mir-15a 
and mir-16-1) in human cancers for the first time. After 
this initial discovery, mir-16-1 and mir-15a were found 
involved and down regulated in most of the CLL (Calin et 
al., 2002), miR143 and miR145 in colon carcinomas 
(Michael et al., 2003) and Let-7 in human lung carci-
nomas (Takamizawa et al., 2004). Some of the miRNAs 
are also found up regulated in human cancers like 
miR155 in Burkitt's lymphoma and some others as well 
(Metzler et al., 2004; Eis et al., 2005). The vital role of 
miRNAs in human cancer is further supported by the 
findings of majority of miRNAs genes located at chro-
mosomal regions that are genetically altered in carci-
nogenisis (Calin et al., 2004).  
Cancer is the ultimate consequence of disordered gene 
expression. microRNAs are suggested to play key role in 
cancer development, however, their precise biological 
roles are still poorly understood. It is therefore, suggested 
that the relevance of these small regulators in different 
types of human carcinomas may be presently under-





connections of miRNAs with different aspects of cancers.  
 
 
miRNA IN HUMAN COLON CANCER/COLORECTAL 
CANCER 
 
Colon cancer is globally ranked second by causing 
cancer related deaths (Jemal et al., 2008; Ramana et al., 
2010) with an estimated 1 million new cases and half a 
million deaths each year (Parkin et al., 2005). Develop-
ment of colon cancer is a stepwise process causing 
anomalies in various genetic and epigenetic processes. 
Tumerogenesis are mostly caused by chromosomal 
instability and damaged DNA repair system, most 
commonly in MLHI, MSH2, MSH6 and PMS2 (Baudhuin 
et al., 2005). Modern research has documented the 
involvement of miRNA in different types of cancers 
including colon cancer (Bandres et al., 2007; Zhang et al. 
2007). To explore the link of miRNA, colon cancer needs 
further detailed studies (Michael et al., 2003) because 
ambiguities exist about the exact nature of aberrant 
miRNA expression pattern (Lu et al., 2005; Volinia et al., 
2006). Colon cancer is caused either by overexpression, 
silencing or switching off of specific miRNA involved in its 
pathogenesis (Rossi et al., 2009).   
Many oncogenic and tumor suppressor pathways 
involved in colon cancer are regulated by miRNA. Majo-
rity of key signaling proteins of colon cancer pathways, 
like members of the Wnt/β-catenin and phosphatidy-
linositol-3-kinase (PI-3-K) pathways, KRAS, p53, etc are 
regulated and affected by miRNA (Fearon and 
Vogelstein, 1990). 
In human, cancers mutations have been recorded in 
the expression of large number of miRNAs including miR-
1, miR-31, miR-133a, miR-135b, miR-182, miR-183, miR-
96 and miR-592. Increased differential methylation has 
been studied in genomic regions having differentially 
expressed micro RNAs in colon cancer (Sarver et al., 
2009). miR-145, miR-20a and miR-92 are the three most 
dysregulated miRNAs in colon cancers, among which 
miR-145 showed reduced expression, while miR-20a and 
miR-92 were up-regulated (Schepeler et al., 2008). mir-
200a, mir-200b and mir-200c are also observed up-
regulated in all colon cancers. The putative targets 
analysis of these miRNAs showed MLH1 and MSH2 as 
two candidate genes which are negatively regulated by 
them. Modern research has also reported differential 
expression of let7-family in colon cancers (Cummins et 
al., 2006; Akao et al., 2006). miR-145 identified as a 
specific miRNA negatively regulated in colon cancers 
(Michael et al., 2003; Cummins et al., 2006) with putative 
targets having oncogenic functions are FOS, MYCN, YES 
and FLI, cell cycle promoters such as cyclins D2 and L1 
and MAPK transduction proteins such as MAP3K3 and 
MAPK4K4 (Iorio et al., 2005).  
CHES1 protein which belongs to the forkhead family of 
transcription   factors   repressing   apoptotic  genes  was  




identified as a potential target for miR-96 and miR-182 
(Bandrés et al., 2006). Over-expression of miR-21 has a 
central role in colon cancers (Schetter et al., 2008; Slaby 
et al., 2007) and regulates cell cycle and checkpoint 
activation through Cdc25A (Wang et al., 2009). miR-143 
plays its function by targeting DNMT3A, which is involved 




miRNAs IN THYROID AND PAPILLARY THYROID 
CANCERS 
 
Significant differences in miRNA expression have been 
observed in various thyroid
 
tumors. A correlation between
 
somatic mutations and miRNA expression was found to 
exist in papillary carcinomas and it was also found that a 
set of miRNAs including miR-146b, miR-155, miR-187, 
miR-197, miR-221,
 
miR-222 and miR-224 over-expressed 
differentially in them (Nikiforova et al., 2008). Papillary 
thyroid cancers (PTC) accounting for about 80% of all 
thyroid cancers are genetically characterized by 
mutations in the RET/PTC-RAS-BRAF signaling pathway 
(Melillo et al., 2005). BRAF and RET/PTC genes muta-
tions during rearrangements are most common in PTC 
tumors (Fusco et al., 2005) and a number of miRNAs are 
also transcriptionally upregulated in these tumors. Five 
miRNAs, miR-146, miR-221 and miR-222 have been 
unequivocally distinguished between normal thyroid and 
PTC. Enhanced regulation of miR-146, miR-221 and 
miR-222 cause a dramatic loss of KIT transcript and 
related protein due to single nucleotide mutations in 
recognition sequences of KIT for these miRNAs. It is 
therefore, suggested that upregulation of numerous 
miRNAs and KIT down regulation are involved in the 
pathogenesis of PTC (Iliopoulos et al., 2005).  
Overexpression of several micro RNAs were the initial 
evidences of their involvement in papillary thyroid can-
cers (He et al., 2005). miRNAs which are up-regulated in 
papillary thyroid cancers included miR-146, miR-221, 
miR-155, miR-34 and miR-181. These miRNAs donor 
show equal expression in this type of tumors but are 
found up-regulated in tumors with BRAF mutation 
(Pallante et al., 2006). It has also suggested that altered 
miRNAs might be early factors with the major role in the 
tumorigenesis of papillary thyroid cancers. There is also a 
genetic association between PTC and a SNP 
(rs2910164) in the precursor of miR-146a. Individuals 
which are heterozygous for the said SNP had an in-
creased risk of acquiring PTC (Jazdzewski et al., 2008).  
miR-181b has been confirmed to be overexpressed
 
in 
all types of follicular cell-derived thyroid tumors
 
and also 
in thyroid hyperplastic nodules. Several other miRNAs 
were also found up-regulated in PCs including miR-187, 
which is the most up-regulated in tumors with RET/PTC 
rearrangement and RAS mutations. It showed signifi-
cantly reduced levels in tumors harboring BRAF mutation 




(Nikiforova et al., 2008). miR-197
 
and miR-346 also 




miRNA IN BREAST CANCER 
 
Breast cancer is a heterogeneous disease with multi step 
progression and constituting progressive changes in the 
genetics of normal tissues, resulting in invasive and 
metastatic carcinoma (Ramaswamy et al., 2009). Studies 
have revealed a fine balance of miRNAs causing stimu-
lation and inhibition of metastasis (Iorio et al., 2005) and 
their involvement in breast cancer invasion (Ma et al., 
2007).  
In breast cancer tissues, 29 miRNAs have been 
identified with significant deregulation in their expression 
level (Iorio et al., 2005). Nine miRNAs, hsa-miR-21, hsa-
miR-365, hsa-miR-181b, hsa-let-7f, hsa-miR-155, hsa-
miR-29b, hsa-miR-181d, hsa-miR-98 and hsa-miR-29c 
were found with more than two fold enhanced level of 
expres-sion, while seven miRNAs, hsa-miR-497, hsa-
miR-31, hsa-miR-355, hsa-miR-320, rno-mir-140, hsa-
miR-127 and hsa-miR-30a-3p were down-regulated more 
than two fold in breast cancer (Yang  et al., 2008). 
Enhanced expression of miR-10b promotes metastasis 
and invasion, whereas its down regulation causes most 
breast cancers. Tumors with miR-10b over expression 
were highly vascularized and showed invasive behavior 
(Ma et al., 2007). miR-373 and miR-520c stimulate 
cancer cell invasion and migration which were previously 
considered associated with testicular cancers (Huang et 
al., 2008). Reduced cell growth has also been proved 
experimentally due to mir-21 inhibition in MCF-7 breast 
cancer cells (Frankel et al., 2008). 
 
 
ROLE OF miRNAs IN GASTRIC CANCER 
 
Gastric cancer is the second
 
most common malignancy 
responsible for approximately 10% of tumor related
 
deaths (Parkin et al., 2005). The molecular
 
pathology of 





kinases (Cdks) along with 
their modulators cause transitions between phases of 
cell-cycle. Cdks can be controlled
 
by Cdk inhibitors (CKIs) 
that bind to Cdks. In mammalian
 
cells, two families of Cdk 
inhibitors are responsible for regulating
 
different Cdks. 











) bind to Cdk4 and Cdk6/cyclin D complexes,
 





proteins block the progression 
through all stages of G1/S, thereby
 
functioning as a 





speculated that the miRNAs can also play related 
biological functions. miRNAs in two clusters (miR-106b
93
 














miR-25 targets p57 through the 3'-UTR. Furthermore, 
miR-106b
 
and miR-93 control p21, while miR-222 and 
miR-221 regulate both
 
p27 and p57. Ectopic expression 
of these miRNAs results in activation
 
of Cdk2 and 
facilitation of G1/S phase transition. Consistent
 
with these 
results, both clusters are abnormally upregulated
 
in 
gastric cancer tissues compared with the corresponding 
normal
 
tissues (Kim et al., 2009). 
Helicobacter pylori infection was thought to be the most 
important factor for gastric carcinogenesis. It has been 
shown that expression of miR-21 was upregulated in the 
patients who got H. pylori infection, implying that the 
pathogen infection induces carcinogenesis in the 
stomach probably due to abnormal expression of some 
oncomiRs such as miR-21. Aberrant expression of miR-
21 can alter multiple biological processes of human 
gastric cancer cells such as proliferation, apoptosis, 
migration and invasion through regulating RECK and 
other critical target genes (Akao et al., 2006).  
 
 
miRNAs IN LUNGS CANCER 
 
Lung cancer is one of the main causes of cancer related 
deaths for men and women world wide (Bommer et al., 
2007). There are two main histological groups of LC that 
is, small cell lung cancer accounting for 15% and non 
small cell lung cancer accounting for 85%. The later one 
is further subdivided into adenocarcinomas, squamous 
cell, large cell and bronchoalveolar carcinomas (Wang et 
al., 2009).  
Gene expression is regulated by miRNAs which are 
found deregulated in different cancers including lung 
cancer (Ma et al., 2007). Hypermethylation is responsible 
for the silencing of tumor suppressor genes, such as 
CDKN2A, CDH13 (Ulivi et al., 2006), FHIT, WWOX 
(Fabbri et al., 2005), CDH1 and RASSF1A (Suzuki et al., 
2004). Methylation of the epigenome is controlled by 
DNA methyltransferases (DNMTs). Three catalytically 
active DNMTs (Dnmt1, Dnmt3A and Dnmt3B) have been 
identified in mammals (Jeltsch, 2002). It has been 
demonstrated that expression of miR-29a, miR-29b and 
miR-29c is down-regulated in NSCLCs (Volinia et al., 
2006), while the mRNA levels of DNMT1 and DNMT3B 
have been found to be elevated by 58% in 102 NSCLCs 
(Kim et al., 2006). According to the available results, the 
expression of miR-29c in lung cancer tissues is inversely 
correlated to the expression of DNMT3A and DNMT 3B 
(Fabbri et al., 2007).  
It has been reported that 28 miRNAs including miR-
145, miR-181c, miR-30 family, miR-140, miR-143, miR-
125, miR-126, miR-101, miR-95, miR-9 and miR-125a 
were down-regulated and 15 miRNAs including miR-210 
were up-regulated in lung cancers (Son et al., 2009). In 
uterine leiomyomas, racial differences were reported in 





number of miRNAs significantly regulated differentially 
between white and black women (Wang et al., 2006). 
miRNAs  miR-376b, miR-144, miR-520d-5p, miR-520e, 
miR-520f, miR-23a, miR-296-5p, miR-133a-2, miR-99b, 
miR-497, miR-425 and miR-338-3p expressions are 
reduced, while miR-371-3p is up-regulated in the earlier 
mentioned case. It has also been shown that in NSCLCs, 
miR-99b was deregulated which was negatively 
correlated with the expression of FGFR3 which has been 
reported to be frequently over expressed in NSCLC cell 
lines. It is therefore suggested that through up-regulation 
of FGFR3, miR-99b may possibly be involved in lung 
tumorigenesis (Son et al., 2009).  
 
 
miRNAs IN PROSTATE CANCER 
 
The most frequently diagnosed cancer among American 
males is the prostate cancer (PCa) (Jemal et al., 2008). 
Till date, the pathogenesis of PCa have been explained 
by several mechanisms (Nelson et al., 2003) and it was 
found that the consequences of  PCa development are 
genetic and epigenetic alterations that lead to invasive 
carcinoma (Li, 2007). In prostate cancer, microRNAs are 
significantly altered which suggests their role as key 
regulators in the process (Coppola et al., 2010). 
Researchers have investigated dysregulation of miRNAs 
in PCa and are trying to establish a connection with the 
emergence and development of the disease through 
miRNA expression profiles (Gandellini et al., 2010).  It is 
now clear that miRNAs express differentially in androgen-
dependent and androgen-independent PCa cells (Lin et 
al., 2008). They are also found to play a role in the 
transition of PCa to the androgen-independent stage (Shi 
et al., 2007). It is therefore essential to have closer 
validation for the role of miRNAs and their differential 
expression patterns in both androgen-dependent and 
androgen-independent PCa cells (Sikand et al., 2009).  
Level of miR-23a and 23b decreased significantly in 
human prostate cancer (Porkka et al., 2007). It was also 
found that in PC3 PCa cells this decrease is due to the 
transcriptional repression by c-Myc (Fujita et al., 2008) 
which leads to upregulation of glutamine catabolism. 
Expression of miR-101 gets decreased due to the loss of 
one or both of the loci encoding it (Varambally et al., 
2008). Genomic losses of miR-101 have been found in 
approximately 37.5% of the localized PCa and 66.7% of 
the metastatic cases. miR-101 is the inhibitor of a 
polycomb group member which is an enhancer of zeste 
homolog-2 (EZH2). It suggests that genomic loss of miR-
101 leads to over expression of EZH2 and abnormal 
regulation of various epigenetic pathways, resulting in 
progression of the disease. miR-449a is a tumor 
suppressor (Noonan et al., 2009) and is down regulated 
in PCa tissues. When miR-449a was introduced into PC-
3 PCa cells, they were observed with apoptosis, cell-
cycle   arrest  and  a  senescent-like  phenotype.  HDAC1  




frequently over express in PCa but is directly targeted by 
miR-449a. (Weichert et al., 2008). 
 
 
miRNAs IN OVARIAN CANCERS 
 
Since the last thirty years, ovarian cancer is still a leading 
cause of mortality. Epithelial ovarian cancer (EOC), a 
type of ovarian cancer, (Corney and Alexander, 2009) is 
the sixth world most common cancer in women causing 
almost 125,000
 
deaths/year (Cannistra, 2004). Its high
 
rate of mortality is mainly due to late diagnosis
 
(Feeley 
and Wells, 2001). Aberrant expression or mutation of 
miRNAs in cancers have proved their importance as a 
class of oncogenes or tumor suppressors (Johnson et al., 
2005) and therefore, implicated in ovarian cancer 
research (Iorio et al., 2007). It is now proved from the 
research that different miRNAs are involved in different 
stages of ovarian cancers. 
When compared with normal ovaries, serous and endo-
metrioid histotypes commonly shared down regulation of 
miR-9. Expression profiling of human immortalized 
ovarian surface epithelial and EOC have showed up-
regulation
 
of miR-214, miR-199a and miR-200a, while 
down-regulation of miR-100. It is also been observed that 
alterations of miR-214, miR-199a and miR-200a are 
associated with advanced stage ovarian tumors. It means 
that up-regulation of miR-214, miR-199a and miR-200a 
participate in progression rather than initiation of ovarian
 
tumor (Yang et al., 2008). It as also been shown that 
miRNAs are histotype specific. miR-21, miR-182 and 
miR-205 have over expressed, miR-144, miR-222 and 
miR-302a have reduced expression in endometrioid 
tumors (Iorio et al., 2007). miRNA-21, miRNA-29a, 
miRNA-92, miRNA-93 and miRNA-126 were over 
expressed while miRNA-127, miRNA-155 and miRNA-
99b expression were observed reduced in the serum of 
individuals with ovarian cancers (Resnick, 2009). miR-
200a, miR-200b, miR-200c, miR-20a, miR-21, miR-23a, 
miR-23b, miR-27a, miR-141, miR-16 and miR-93 have 
over expressed, while miR-214, miR-26a, miR-29a, let-
7b, miR-100, miR-10b, miR-125a, miR-125b, miR-143, 
miR-145, miR-199a-AS and miR-99a have found to be 




FUTURE PERSPECTIVES AND THERAPEUTIC 
POTENTIALS 
 
Soon after the discovery of miRNAs, it became clear that 
they play important roles in many cellular processes. 
Modern research in the miRNA biology have provided us 
with improved understanding towards microRNA bio-
genesis, regulation, function and their association with 
molecular pathogenesis of diverse and complex diseases 
like   cancer,   cardiac   disorders,   viral    infections   and  




metabolic disorders. Though, more than 530 miRNAs 
have been identified in human, much remains to be 
understood about their precise cellular function and role 
in the development of diseases. Scientists try to explore 
the mystery of miRNA biology and its potential as 
therapeutic agents. High-throughput target analysis com-
bining genomics and proteomics might help delineating 
the spectrum of targets that are regulated by miRNAs. 
microRNA based cancer therapy is considered as an 
alternative for targeting gene networks regulated by a 
single miRNA. Recently, it has been suggested that 
specific microRNAs can a play role in drug resistance in 
various cancer cell lines. Altered regulation of specific 
microRNAs can provide information about resistance and 
sensitivity of tumors to different treatments.  
New knowledge about the functional roles of oncomiRs 
is revolutionizing cancer biology and will open up new 
horizons in biomedical research. Further studies are 
therefore necessary to verify the mechanistic details in 
biological functions of microRNAs. A considerable invest-
ment in microRNA research is required to use miRNAs as 
novel biomarkers and new therapeutic targets and tools 
can be formulated. Rapid expansion in this field suggests 
their impact on the management of cancer patients in the 
near future. As an emerging technology, miRomics has a 
great potential to be utilized in drug development. In 
simple words, development in microRNA field, these 
small players could be worthless tools for different areas 
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